Intraperitoneal Instillation of Levobupivacaine With Morphine Versus Levobupivacaine With Magnesium Sulfate for Postoperative Analgesia
Primary Purpose
Post Operative Pain
Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
intraperitoneal levobupivacaine and morphine
Sponsored by
About this trial
This is an interventional prevention trial for Post Operative Pain
Eligibility Criteria
Inclusion Criteria:
- Patients who were scheduled for L.C,
- Ages 18 and 60 years
- ASA I-II and
- BMI 19 - 39
Exclusion Criteria:
- Patients with hepatic or renal dysfunction
- use of opioids 24 hrs prior to the study
- treatment with steroids prior to surgery
- drug or alcohol abuse, allergy to any of the study drugs
- chronic pain syndrome as a result of neurological disease
Sites / Locations
- Khalid abdelal
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
levobupivacaine with morphine
levobupivacaine with magnesium sulfate
Arm Description
30 patients will have intraperitoneal instillation of levobupivacaine with added morphine at the end of laparoscopic cholecystectomy operation
30 patients will have intraperitoneal instillation of levobupivacaine with added magnesium sulfate at the end of laparoscopic cholecystectomy operation
Outcomes
Primary Outcome Measures
reduction of postoperative pain
reduction of post operative visual analogue score
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05281081
Brief Title
Intraperitoneal Instillation of Levobupivacaine With Morphine Versus Levobupivacaine With Magnesium Sulfate for Postoperative Analgesia
Official Title
Comparison of Intra-Peritoneal Instillation of Levobupivacaine With Morphine Hydrochloride Versus Levobupivacaine With Magnesium Sulfate for Post-Operative Pain Relief After Laparoscopic Cholecystectomy
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
August 1, 2021 (Actual)
Study Completion Date
December 1, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sohag University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a prospective randomized study that included 60 patients and was divided into two equal groups of patients who were scheduled for LC, Ages 18 and 60 years, both sexes, ASA I-II and BMI 19 - 39. Group A received 30 ml levobupivacaine (0.25%) plus 3 mg morphine intraperitoneal at the site of surgery in the bed of the gallbladder via the navel port with the patient in a Trendelenburg position, Group B received 30 ml levobupivacaine (0.25%) plus 50 mg/kg magnesium sulfate in the same pattern as in the A group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Operative Pain
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
levobupivacaine with morphine
Arm Type
Active Comparator
Arm Description
30 patients will have intraperitoneal instillation of levobupivacaine with added morphine at the end of laparoscopic cholecystectomy operation
Arm Title
levobupivacaine with magnesium sulfate
Arm Type
Experimental
Arm Description
30 patients will have intraperitoneal instillation of levobupivacaine with added magnesium sulfate at the end of laparoscopic cholecystectomy operation
Intervention Type
Drug
Intervention Name(s)
intraperitoneal levobupivacaine and morphine
Intervention Description
istillation of the peritoneum with levobupivacaine mixture with morphine
Primary Outcome Measure Information:
Title
reduction of postoperative pain
Description
reduction of post operative visual analogue score
Time Frame
8 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who were scheduled for L.C,
Ages 18 and 60 years
ASA I-II and
BMI 19 - 39
Exclusion Criteria:
Patients with hepatic or renal dysfunction
use of opioids 24 hrs prior to the study
treatment with steroids prior to surgery
drug or alcohol abuse, allergy to any of the study drugs
chronic pain syndrome as a result of neurological disease
Facility Information:
Facility Name
Khalid abdelal
City
Sohag
ZIP/Postal Code
532
Country
Egypt
12. IPD Sharing Statement
Learn more about this trial
Intraperitoneal Instillation of Levobupivacaine With Morphine Versus Levobupivacaine With Magnesium Sulfate for Postoperative Analgesia
We'll reach out to this number within 24 hrs